Evolv Technologies, a US-based biotechnology firm, has seen its stock price plummet to a 52-week low of 0.05 USD per share, sparking concerns among investors.
The company's shares have been underperforming in recent months, with significant losses for investors who bought into the stock at higher prices.
According to various financial news outlets, Evolv Technologies has been struggling to generate revenue and make a profit despite its innovative products in the field of biotechnology.
The firm's share price has lost over 90% of its value in the past year alone, with many investors now holding onto their shares at a significant loss.
Experts have speculated that Evolv Technologies' struggling share price could be due to several factors, including stiff competition from established players in the industry and regulatory challenges.